Effects of 3-Glucosaminoglycan Sulfate on Hemorheologic Parameters in Hyperlipidemic Peripheral Vascular Disease (PVD) Patients

Ciuffetti, Giovańni; Mercuri, Michele; Susta, A; Lupattelli, Graziana; Pasqualini, Leonella; Lombardini, Rita

doi:10.1177/0003319789040004032

Cited by 9 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[35][36][37][38][39][40][41][42][43][44] Several clinical studies indicate the clinical efficacy, safety, and tolerability of sulodexide as an antithrombotic. [45][46][47][48][49][50][51] On the basis of our study, recurrent DVTwhich is common and may also lead to pulmonary embolism -can be effectively controlled or reduced and prevented by sulodexide treatment. 52 In controlled conditions, for established treatments, clinical registries are comparable to clinical trials and can be organized at a reasonable cost.…”

Section: Discussionmentioning

confidence: 99%

Prevention of Recurrent Deep Venous Thrombosis with Sulodexide: The SanVal Registry

Errichi

Cesarone²,

Belcaro³

et al. 2004

Angiology

View full text Add to dashboard Cite

The aim of this study was to evaluate the prevention of recurrent deep vein thrombosis (R-DVT) with an oral antithrombotic agent (sulodexide) in moderate to high-risk subjects. A group of 405 patients was included into the multicenter registry. Both compression and an exercise program were used as well as a risk-factors control plan. After diagnosis of DVT, patients were treated with oral anticoagulants for 6 months. At the end of this period a coagulation study was made and patients started treatment with oral sulodexide capsules for a period of 24 months. The femoral, popliteal, tibial, and superficial veins were scanned with high-resolution ultrasound at inclusion;scans were repeated at 6, 12, 18, and 24 months. Of the 405 subjects included into the registry 178 in the control group (mean age 52.2; SD 11; M:F=90:88) and 189 in the treatment group (mean age 53.2; SD 10.3; M:F=93:96) completed the analysis period of 24 months. At 6 and 12 months the incidence of R-DVT was lower (p<0.05) in the treatment group. At 24 months the global incidence of R-DVT was 17.9% in the control group and 7.4% in the sulodexide group (p<0.05), 2.42 times lower than in controls. The 2 groups were comparable for age and sex distribution and for the localization of the thrombi at inclusion. Also the 2 groups of dropouts were comparable. In the control group there were 32 recurrent DVTs and 24 subjects lost to follow-up (total of 56) of 202 included subjects (27.7%) in comparison with 28 failures (14 recurrent DVTs and 14 lost subjects) of 203 subjects (13.8%) in the treatment group. This difference was statistically significant. In this analysis the incidence of DVT in controls was 2.07 times higher than in the treatment group subjects. In conclusion sulodexide was effective in reducing recurrent thrombotic events in high-risk subjects.

show abstract

Section: Discussionmentioning

confidence: 99%

Prevention of Recurrent Deep Venous Thrombosis with Sulodexide: The SanVal Registry

Errichi

Cesarone²,

Belcaro³

et al. 2004

Angiology

View full text Add to dashboard Cite

show abstract

“…Research on the hyperviscosity phenomena in arterial vascular structures and their modification by sulodexide is particularly interesting. Many studies have found that sulodexide significantly reduces viscosity after intramuscular (IM) administration followed by long-term oral administration 35–42…”

Section: Pharmacodynamicsmentioning

confidence: 99%

“…Many studies have found that sulodexide significantly reduces viscosity after intramuscular (IM) administration followed by long-term oral administration. 35 – 42 …”

Section: Pharmacodynamicsmentioning

confidence: 99%

Use of sulodexide in patients with peripheral vascular disease

J¹,

Coronel²,

Aza³

et al. 2010

JBM

View full text Add to dashboard Cite

Sulodexide is a highly purified glycosaminoglycan containing a combination of heparan sulfate with affinity for antithrombin III and dermatan sulfate with affinity for heparin cofactor II. This antithrombotic and antithrombin activity is of great pharmacologic interest and makes sulodexide a suitable drug for the prophylaxis and treatment of arterial and venous peripheral diseases. In arterial pathology, changes in the Winsor Index, improvement in peripheral blood flow, and reduction in pain-free walking distance confirm that treatment with oral sulodexide is effective. Lipid components linked to the genesis of peripheral vascular processes, including triglycerides, total cholesterol, and low-density lipoprotein fractions, as well as plasma and blood viscosity, are reduced by the administration of sulodexide, whereas the high-density lipoprotein fraction increases. Sulodexide inhibits aggregation and adhesion of platelets at the level of the vascular wall, reduces plasma fibrinogen concentrations, reduces plasminogen activator inhibitor-1, and increases tissue plasminogen activator, as well as systemic fibrinolytic and thrombolytic activity, thereby demonstrating efficacy in the treatment of thromboembolic disease. There is no interaction between sulodexide and other drugs used as long-term treatment for peripheral vascular disease. It is well tolerated, and the adverse reactions described after oral administration are related mainly to transient gastrointestinal intolerance, ie, nausea, dyspepsia, and minor bowel symptoms. Sulodexide may become the treatment of choice when dealing with vascular diseases and their complications, as well as for the prevention of venous thromboembolic disease, being particularly indicated in elderly patients, due to its good tolerability and ease of management.

show abstract

“…A dose-dependent decrease in plasma and whole blood viscosity was demonstrated after oral administration in patients with chronic venous disease 44 and in patients with peripheral vascular disease. [46][47][48] It is also worth mentioning a study of the effect of some glycosaminoglycans (including sulodexide) on elevated plasma fibrinogen levels in diabetic patients. 49 The parenteral administration, to type II diabetic subjects, of 12,500 IU of heparin, 7500 IU of low-molecular-weight heparin, 50 mg of der-10 • HARENBERG matan sulfate, or 40 mg (equal to 400 LRU) of sulodexide, for 10 days, resulted in a decrease in plasma fibrinogen concentrations by about 50 mg% compared to placebo, in all groups.…”

Section: P H a R M A C O K I N E T I C S A N D P H A R M A C O D Y N mentioning

confidence: 99%

Review of pharmacodynamics, pharmacokinetics, and therapeutic properites of sulodexide

Harenberg

1998

Med. Res. Rev.

View full text Add to dashboard Cite

Effects of 3-Glucosaminoglycan Sulfate on Hemorheologic Parameters in Hyperlipidemic Peripheral Vascular Disease (PVD) Patients

Cited by 9 publications

References 5 publications

Prevention of Recurrent Deep Venous Thrombosis with Sulodexide: The SanVal Registry

Prevention of Recurrent Deep Venous Thrombosis with Sulodexide: The SanVal Registry

Use of sulodexide in patients with peripheral vascular disease

Review of pharmacodynamics, pharmacokinetics, and therapeutic properites of sulodexide

Contact Info

Product

Resources

About